pomalidomide has been researched along with Heart Failure in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adamu, H; Arnall, JR; Bhutani, M; Mishkin, J; Usmani, SZ | 1 |
| Buadi, F; Detweiler-Short, K; Dingli, D; Dispenzieri, A; Gertz, MA; Hayman, S; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Lust, JA; Rajkumar, SV; Russell, SJ; Zeldenrust, S | 1 |
2 other study(ies) available for pomalidomide and Heart Failure
| Article | Year |
|---|---|
Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Topics: Adult; Antibodies, Monoclonal; Cyclophosphamide; Dexamethasone; Female; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2019 |
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.
Topics: Amyloid; Amyloidosis; Biomarkers; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Heart Failure; Humans; Immunoglobulin Light Chains; Immunologic Factors; Lenalidomide; Melphalan; Natriuretic Peptide, Brain; Patient Dropouts; Peptide Fragments; Stem Cell Transplantation; Thalidomide; Troponin T | 2010 |